DVA · News · 20260805N
Products and Technology
DAVITA INC. · 2026-08-05 · Importance 31 · Surprise 42 · In source text
DaVita is expanding access to Expanded Hemodialysis and continuing hemodiafiltration pilots to improve removal of middle molecules and support more personalized kidney care. The rollout follows FDA approval of Nipro’s ELISIO-HX dialyzer, which is compatible with existing dialysis machines and provides greater middle-molecule clearance. The company is positioning the technology to address chronic inflammation, cardiovascular complications and symptom burden associated with larger uremic toxins.
Key facts
- DaVita is rapidly scaling access to Expanded Hemodialysis (Expanded HD) therapies and continuing hemodiafiltration (HDF) pilots following the FDA approval of Nipro's ELISIO-HX dialyzer. source
- DaVita said it has secured supply for advanced dialyzers. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | DaVita is rapidly scaling access to Expanded Hemodialysis (Expanded HD) therapies and continuing hemodiafiltration (HDF) pilots following… |